Online Exclusive Article

Relative Dose Intensity—Improving Treatment and Outcomes in Early-Stage Breast Cancer: A Retrospective Study

Deborah A. Griffin

Barbara Penprase

Justin F. Klamerus

treatment, oncologic and outcomes research, breast neoplasms
ONF 2012, 39(6), E459-E467. DOI: 10.1188/12.ONF.E459-E467

Purpose/Objectives: To determine the amount of chemotherapy delivered compared to amount of chemotherapy scheduled by calculating relative dose intensity (RDI) and to identify factors associated with nonadherence of scheduled treatment regimens for patients with early-stage breast cancer (ESBC).

Design: Retrospective, descriptive, correlational study.

Setting: Two community hospital cancer centers in northern Michigan.

Sample: 77 patients with ESBC receiving adjuvant chemotherapy.

Methods: The RDI Calculator™ was used for data collection. A worksheet was developed for each patient and included characteristics, treatment information, and RDI calculations. SAS®, version 19.2, was used for multivariate analyses based on logistical regression analyzing relationships among dependent and independent variables.

Main Research Variables: Dependent variables were RDI prescribed and RDI received. Independent variables included chemotherapy regimen, clinical characteristics, planned dose, and schedule.

Findings: The average RDI was 86.6%. The average RDI was 86.7% for patients younger than age 65, and 85.5% for those 65 and older. The most common reasons for dose reduction or dose delay were treatment toxicity, chronic disease risk factors, age, unplanned versus planned treatment dose, institution (different standards of care), patient preference, and weight.

Conclusions: Meeting treatment goals of RDI for patients with ESBC has been shown to increase the disease-free survival rate and positively affects overall survival.

Implications for Nursing: Nurses have the unique opportunity to case manage patients with ESBC throughout the spectrum of care. One of the key areas of focus is education of the patient and her family members from the time of diagnosis throughout treatment and rehabilitation.

Jump to a section


    Adisa, A., Lawal, O., & Adesunkanmi, A. (2008). Evaluation of patients' adherence to chemotherapy for breast cancer. African Journal of Health Sciences, 15, 22-27. doi:10.4103/0973-1482.42640
    Adjuvant Breast Cancer Trials Collaborative Group. (2007). Polyche-motherapy for early breast cancer: Results from the international adjuvant breast cancer chemotherapy randomized trial. Journal of the National Cancer Institute, 99, 506-515.
    American Cancer Society. (2012). Cancer facts and figures, 2012. Atlanta, GA: Author.
    American College of Surgeons. (2009). Commission on Cancer: Cancer program standards (Revised edition). Retrieved from
    Bonadonna, G., Moliterni, A., Zambetti, M., Daidone, M., Pilotti, S., Gianni, L., & Valaqussa, P. (2005). 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: Cohort study. BMJ, 330, 217-222.
    Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., & Brambilla, C. (1995). Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. New England Journal of Medicine, 332, 901-906. doi: 10.1056/NEJM199504063321401
    Burns, N., & Grove, S. K. (2009). The practice of nursing research (6th ed.). New York, NY: W. B. Saunders.
    Chirivella, I., Bermejo, B., Insa, A., Perez-Fidalgo, A., Magro, S., Rosello, E., … Lluch, A. (2006). Impact of chemotherapy dose-related factors on survival in breast cancer patients treated with anthracycline-based chemotherapy [Abstract 668]. Journal of Clinical Oncology, 24(18, Suppl.). Retrieved from…
    Crawford, J., Dale, D., Kuderer, N., Culakova, E., Poniewierski, M., Wolff, D., & Lyman, G. H. (2008). Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: The results of a prospective nationwide study of oncology practice. Journal of the National Comprehensive Cancer Network, 6, 109-118.
    Dale, D., McCarter, G., Crawford, J., & Lyman, G. (2003). Myelotoxicity and dose intensity of chemotherapy: Reporting practices from randomized clinical trials. Journal of the National Comprehensive Cancer Network, 1, 440-454.
    DeVita, V., Hellman, S., & Rosenberg, S. (Eds.). (2005). Cancer: Principles and practice of oncology, breast cancer. Philadelphia, PA: Lippincott Williams and Wilkins.
    Early Breast Cancer Trialists' Collaborative Group. (2005). Polyche-motherapy for early breast cancer: An overview of the randomized trials. Lancet, 352, 930-942.
    Gillespie, T. W. (2001). Chemotherapy dose and dose intensity: Analyzing data to guide therapeutic decisions. Oncology Nursing Forum, 28(2, Suppl.), 5-10.
    Griggs, J., Culakova, E., Sorbero, M., Poniewierski, M., Wolff, D., Crawford, J., … Lyman, G. H. (2007). Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. Journal of Clinical Oncology, 25, 2522-2527. doi:10.1200/JCO.2006.10.2749
    Hryniuk, W., Frei, E., & Wright, F. A. (1998). A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: Summation dose-intensity. Journal of Clinical Oncology, 16, 3137-3147.
    Jansen, S., Kievit, J., Nooij, M., de Haes, J., Overpelt, I., van Slooten, H., … Stiggelbout, A. M. (2001). Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: Is treatment worthwhile? British Journal of Cancer, 84, 1577-1585. doi:10.1054/bjoc.2001.1836
    Lenhart, C. (2005). Relative dose intensity: Improving cancer treatment and outcomes. Oncology Nursing Forum, 32, 757-764. doi:10.1188/05.ONF.757-764
    Link, B., Budd, G., Scott, S., Dickman, E., Paul, D., & Lawless, G. (2001). Delivering adjuvant chemotherapy to women with early-stage breast cancer: Current patterns of care. Cancer, 92, 1354-1367. doi:10.1002/1097-0142(20010915)92:6<1354::AID-CNCR1458 >3.0.CO;2-P
    Liu, Z., Doan, Q. V., Malin, J., & Leonard, R. (2009). The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Applied Health Economic Health Policy, 7, 193-205.
    Lohrisch, C., Paltiel, C., Gelmon, K., Speers, C., Taylor, S., Barnett, J., & Olivotto, I. A. (2006). Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. Journal of Clinical Oncology, 24, 4888-4894. doi:10.1200/JCO.2005.01.6089
    Lyman, G. H. (2006). Chemotherapy dose intensity and quality cancer care. Oncology, 20(14, Suppl. 9), 16-25.
    Lyman, G. H. (2009). Impact of chemotherapy dose intensity on cancer patient outcomes. Journal of the National Comprehensive Cancer Network, 7, 99-108.
    Lyman, G. H., Dale, D. C., & Crawford, J. (2003). Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. Journal of Clinical Oncology, 21, 4524-4531. doi:10.1200/JCO.2003.05.002
    Mincey, B., Palmieri, F., & Perez, E. (2002). Adjuvant therapy for breast cancer: Recommendations for management based on consensus review and recent clinical trials. Oncologist, 7, 246-250. doi:10.1634/theoncologist.7-3-246
    National Comprehensive Cancer Network. (2010). NCCN Clinical Practice Guidelines in Oncology: Breast cancer [v.2.2010]. Retrieved from
    National Comprehensive Cancer Network. (2011). NCCN Clinical Practice Guidelines in Oncology: Myeloid growth factors [v.2.2011]. Retrieved from
    Norton, L. (1988). A Gompertzian model of human breast cancer growth. Cancer Research, 48(24, Pt. 1), 7067-7071.
    Norton, L. (1997). Evolving concepts in the systemic drug therapy of breast cancer. Seminars in Oncology, 24(4, Suppl. 10), S10-3-S10-10.
    Oncology Nursing Society. (2010). ONS PEP topics. Retrieved from
    Shayne, M., Crawford, J., Dale, D., Culakova, E., & Lyman, G. (2006). Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Research and Treatment, 100, 255-262. doi:10.1007/s10549-006-9254-4
    Shayne, M., Culakova, E., Wolff, D., Poniewierski, M., Dale, D., Crawford, J., & Lyman, G. (2009). Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer, 11, 5319-5328. doi:10.1002/cncr.24560
    Smith, R. E. (2006). Trends in recommendations for myelosuppressive chemotherapy for the treatment of solid tumors. Journal of the National Comprehensive Cancer Network, 4, 649-658.
    Vogel, C., Wojtukiewicz, M., Carroll, R., Tjulandin, S., Barajas-Figueroa, L., Wiens, B., … Schwartzberg, L. S. (2005). First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology, 23, 1178-1184.
    Ziegler, J., & Citron, M. (2006). Dose-dense adjuvant chemotherapy for breast cancer. Cancer Nursing, 29, 266-272. doi:10.1097/00002820-200607000-00002